Merck KGaA
MKKGYDrugs in Pipeline
36
Phase 3 Programs
15
Upcoming Catalysts
1
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
F0434
Diabetic Neuropathies
Cilengitide
Glioblastoma
Avelumab
Carcinoma, Hepatocellular
Single low dose cyclophosphamide
Non-small Cell Lung Cancer
MSJ-0011
Anovulation
Tecemotide (L-BLP25)
Non-small Cell Lung Cancer
Bintrafusp alfa
Advanced Soft-tissue Sarcoma
Saizen®
Idiopathic Short Stature
Docetaxel
Carcinoma, Non-Small-Cell Lung
Cisplatin
Squamous Cell Carcinoma of the Head and Neck
RNF
Multiple Sclerosis
GONAL-f®
Infertility
Enpatoran
Systematic Lupus Erythematosus
M7824
Non-small Cell Lung Cancer
Precemtabart tocentecan
Metastatic Colorectal Cancer
M6223
Locally Advanced or Metastatic Urothelial Carcinoma
M5049
Coronavirus Disease 2019
Tuvusertib (M1774)
Ovarian Cancer
Enpatoran low dose
Systemic Lupus Erythematosus
Atacicept: with loading dose
Rheumatoid Arthritis
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
Infertility Implantation Failure
Pembrolizumab
Metastatic Colorectal Cancer
Cisplatin/Carboplatin
Squamous Cell Carcinoma of the Head and Neck
Tepotinib
Carcinoma, Hepatocellular
GEN-001
Gastric Cancer
M2591 25 mg QD
Rheumatoid Arthritis
Pimasertib
Pancreatic Adenocarcinoma
Peposertib 50 mg
Locally Advanced Rectal Cancer
Nirogacestat
Desmoid Tumor
Cilengitide (2-times weekly)
Glioblastoma
Encorafenib
BRAF V600E
Immune Checkpoint Inhibitor
HCC
Mirdametinib
NF1
Nirogacestat Hydrobromide
Desmoid Fibromatosis
Association of berzosertib with gemcitabine
Leiomyosarcoma, Adult
HMBD-001
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
F0434 | Phase 3 | Diabetic Neuropathies | - | - |
Cilengitide | Phase 3 | Glioblastoma | - | - |
Avelumab | Phase 3 | Carcinoma, Hepatocellular | - | - |
Single low dose cyclophosphamide | Phase 3 | Non-small Cell Lung Cancer | - | - |
MSJ-0011 | Phase 3 | Anovulation | - | - |
Tecemotide (L-BLP25) | Phase 3 | Non-small Cell Lung Cancer | - | - |
Bintrafusp alfa | Phase 3 | Advanced Soft-tissue Sarcoma | - | - |
Saizen® | Phase 3 | Idiopathic Short Stature | - | - |
Docetaxel | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Cisplatin | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
RNF | Phase 3 | Multiple Sclerosis | - | - |
GONAL-f® | Phase 3 | Infertility | - | - |
Enpatoran | Phase 3 | Systematic Lupus Erythematosus | - | - |
M7824 | Phase 3 | Non-small Cell Lung Cancer | - | - |
Precemtabart tocentecan | Phase 3 | Metastatic Colorectal Cancer | - | - |
M6223 | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma | - | - |
M5049 | Phase 2 | Coronavirus Disease 2019 | - | - |
Tuvusertib (M1774) | Phase 2 | Ovarian Cancer | - | - |
Enpatoran low dose | Phase 2 | Systemic Lupus Erythematosus | - | - |
Atacicept: with loading dose | Phase 2 | Rheumatoid Arthritis | - | - |
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) | Phase 2 | Infertility Implantation Failure | - | - |
Pembrolizumab | Phase 2 | Metastatic Colorectal Cancer | - | - |
Cisplatin/Carboplatin | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Tepotinib | Phase 2 | Carcinoma, Hepatocellular | - | - |
GEN-001 | Phase 2 | Gastric Cancer | - | - |
M2591 25 mg QD | Phase 2 | Rheumatoid Arthritis | - | - |
Pimasertib | Phase 2 | Pancreatic Adenocarcinoma | - | - |
Peposertib 50 mg | Phase 2 | Locally Advanced Rectal Cancer | - | - |
Nirogacestat | Phase 2 | Desmoid Tumor | - | - |
Cilengitide (2-times weekly) | Phase 2 | Glioblastoma | - | - |
Encorafenib | Phase 2 | BRAF V600E | - | - |
Immune Checkpoint Inhibitor | Phase 2 | HCC | - | - |
Mirdametinib | Phase 2 | NF1 | - | - |
Nirogacestat Hydrobromide | Phase 2 | Desmoid Fibromatosis | - | - |
Association of berzosertib with gemcitabine | Phase 2 | Leiomyosarcoma, Adult | - | - |
HMBD-001 | Phase 2 | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Merck KGaA's drug pipeline?→
CatalystAlert tracks 36 drug candidates in Merck KGaA's (MKKGY) pipeline across Phase 3, Phase 2. Its lead program is F0434 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Merck KGaA's next FDA catalyst?→
Merck KGaA's (MKKGY) next tracked catalyst is a Phase 2 expected January 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MKKGY biotech catalysts?→
Add MKKGY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Merck KGaA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.